Q2 Earnings Estimate for HURA Issued By Zacks Small Cap

TuHURA Biosciences (NASDAQ:HURA) – Analysts at Zacks Small Cap issued their Q2 2025 earnings estimates for TuHURA Biosciences in a report released on Tuesday, February 4th. Zacks Small Cap analyst J. Vandermosten anticipates that the company will post earnings of ($0.09) per share for the quarter. Zacks Small Cap also issued estimates for TuHURA Biosciences’ Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, Q1 2026 earnings at ($0.17) EPS and Q2 2026 earnings at ($0.17) EPS.

Other equities analysts have also recently issued research reports about the stock. RODMAN&RENSHAW upgraded shares of TuHURA Biosciences to a “strong-buy” rating in a research report on Thursday, December 19th. Rodman & Renshaw began coverage on shares of TuHURA Biosciences in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Maxim Group initiated coverage on shares of TuHURA Biosciences in a research report on Tuesday, November 5th. They set a “buy” rating and a $15.00 price target on the stock.

TuHURA Biosciences Stock Performance

Shares of NASDAQ HURA opened at $4.88 on Wednesday. TuHURA Biosciences has a 1 year low of $2.84 and a 1 year high of $14.60. The company’s 50-day moving average is $4.81.

Institutional Investors Weigh In On TuHURA Biosciences

An institutional investor recently bought a new position in TuHURA Biosciences stock. Apollon Wealth Management LLC acquired a new stake in shares of TuHURA Biosciences (NASDAQ:HURA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 61,772 shares of the company’s stock, valued at approximately $253,000. Apollon Wealth Management LLC owned 0.15% of TuHURA Biosciences as of its most recent SEC filing. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.